← All trials
NCT05943886
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 11, 2021
- Primary completion
- Feb 17, 2023
- Completion date
- Feb 17, 2023
- First posted
- Jul 13, 2023
- Last posted
- Jul 17, 2023
- Enrollment
- 164
- Arms / groups
- 15 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TaiGen Biotechnology Co., Ltd.Lead sponsor
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.